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Abstract: Traditionally, neuropsychological deﬁ  cits due to Sickle Cell Disease (SCD) have been 
understudied in adults. We have begun to suspect, however, that symptomatic and asymptomatic 
Cerebrovascular Events (CVE) may account for an alarming number of deﬁ  cits in this popula-
tion. In the current brief review, we critically evaluated the pediatric and adult literatures on the 
neurocognitive effects of SCD. We highlighted the studies that have been published on this topic 
and posit that early detection of CVE via neurocognitive testing, neuropsychiatric evaluations, 
and neuroimaging may signiﬁ  cantly reduce adult cognitive and functional morbidities.
Keywords: cerebral vascular event, neuropsychological assessment, sickle cell disease, 
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In recent years, our understanding of the neuropathophysiology of sickle cell disease 
(SCD) and its related consequences have progressed signiﬁ  cantly (Edwards, Whitﬁ  eld, 
Sudhakar et al 2006; Pells, Presnell, Edwards et al 2005). Seminal studies such as The 
Cooperative Study of Sickle Cell Disease (CSSCD) (Armstrong et al 1996) have high-
lighted the value of early detection of silent and overt cerebrovascular events (CVE) in 
populations at risk of complications and morbidity (Brown et al 2000). However, we 
have yet to fully explore the cumulative inﬂ  uences of early CVE on neurocognitive 
and adaptive functioning in adults with SCD.
SCD is a class of genetic disorders characterized by sickle-shaped, red blood cells 
that may cause a variety of clinical symptoms with potentially signiﬁ  cant neurological 
and neuropsychiatric sequelae (Brown et al 1993; Broe 2001; Edwards et al 2005). 
Central nervous system (CNS)-related complications of SCD include transient ischemic 
attacks (TIA), seizures, and increased intracranial pressure. The incidence of CNS 
complications among this population varies from 1.3% to 40% (Izoura et al 1989). 
Among the most serious neurological complications associated with SCD are clini-
cally symptomatic strokes and “silent infarctions” (Briscoe 2001). A silent infarction 
is best conceptualized as a CVE in the absence of immediately recognizable signs or 
symptoms.
Silent infarctions can produce neurocognitive deﬁ  cits throughout the lifespan. 
These can result in reduced lifetime capacities for reading and spelling achievement, 
increased number of absences from school and work, and lower performance on IQ 
tests (Schatz, Finke et al 2002; Steen et al 2002). Moreover, given the signiﬁ  cant adult 
consequences of these developmental milestones, early detection of silent and perhaps 
asymptomatic CVEs, may assist to mitigate long-term morbidities and may improve 
adult neurocognitive functioning (Fowler et al 1988; Powars et al 2001).
In North America, complications associated with the sickle cell diseases (SCDs) 
have increased over many years. However, clinical management requirements of Neuropsychiatric Disease and Treatment 2007:3(6) 706
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patients with SCD vary with some requiring frequent hos-
pitalization, constant narcotic medication management, and 
frequent transfusions, whereas others require very few medi-
cal and support resources. Adult complications and expected 
longevity may be functional sequelae of neurodevelopmental 
and childhood hematological crises (Armstrong et al 1996; 
Cohen et al 2004). As such, understanding the effects of 
early CVEs on the neurodevelopmental processes may be 
critical in developing effective management strategies for 
adult morbidities associated with SCD.
Clinically apparent infarctions or CVEs have been found 
to occur in pediatric and adult populations with SCD and 
are associated with diverse sequelae including hemiplegia, 
aphasia, seizures, deﬁ  cits in executive function and language, 
and reduced visuo-perceptual abilities (Izoura et al 1989; 
Ohene-Frempong et al 1998; Hogan, Kirkham et al 2006). 
The developmental effects of pediatric CVE on adult neuro-
cognitive functioning are not well deﬁ  ned or understood but 
are estimated to be consequential (Powars et al 2001). Several 
studies have found deﬁ  cits in general intellectual functioning, 
language and verbal abilities, visual-motor and visual-spatial 
processing, memory, academic achievement, and processing 
of subtle prosodic information in pediatric patients with a 
range of SCD severities and disease-related complicating 
issues (Kral et al 2001; Treadwell et al 2005).
For example, silent or asymptomatic CVEs in pediatric 
patients with SCD can produce subtle deﬁ  cits in attention and 
concentration, executive function, and visual-motor speed 
and coordination (Kral et al 2001). However, it is unclear how 
early and more overt CVEs in patients with SCD affect the 
life course of academic performance, occupational achieve-
ment, adult neurocognitive functioning, mood, and related 
psychosocial outcomes.
Several earlier studies provide evidence for the impact 
of SCD on neurocognitive functioning (Steen et al 2002). 
Fowler et al (1988) noted that children with SCD experienced 
signiﬁ  cantly lower reading and spelling achievement scores 
than healthy controls. Schatz (2004) noted that children with 
SCD are more likely to have academic achievement and 
goal attainment difﬁ  culties when compared to their demo-
graphically matched peers. Wassserman et al (1991) found 
that children with SCD, compared with siblings with sickle 
cell trait or normal hemoglobin, had poorer performance on 
measures of intellectual, academic, and general neuropsy-
chiatric functioning.
More speciﬁ  cally, and in a sample of 43 patients and 30 
sibling controls, siblings with the sickle cell trait performed no 
differently than the normal hemoglobin group (Wassserman 
et al 1991). Patients with SCD had a signiﬁ  cantly higher 
absences missed from school and lower performance on 
IQ tests. Several studies have also noted that children with 
SCD have signiﬁ  cantly poorer cognitive performances on 
measures of visual-motor integration and attention (Schatz, 
Finke et al 2002; Hariman et al 1991). Many studies have 
suggested that these results are at least partially accounted for 
by the fact that 46% of patients with SCD have remarkable 
ﬁ  ndings on MRI and 64% have vasculopathies detectable on 
MRA (Steen, Xiong et al 2003).
Representative of a gradual but notable change in scien-
tiﬁ  c thinking, Steen, Emudianughe et al (2003) purported 
that sickle cell trait may not be as innocuous as once thought, 
and may predispose African Americans and other popula-
tions susceptible to this genetic disease to increased risk of 
vasculopathies and stroke. Consequently, subtle vascular 
abnormalities and moderately decreased hematocrit levels are 
evidenced in many individuals who are trait positive and the 
impact of this subclinical status on cognitive and psychiatric 
functioning is relatively unknown (Steen et al 1999).
Consistent with previous research, we propose that there 
may be a high rate of unidentiﬁ  ed brain abnormalities possi-
bly secondary to silent CVE in patients with SCD (Baldeweg 
et al 2005; Schatz, White et al 2002; Schatz and McClellan 
2006; Schatz et al 1999). This conclusion has been partially 
supported by the work of many researchers including Steen 
and colleagues (Steen et al 1999; Steen, Emudianughe et al 
2005) who have demonstrated that patients with SCD exhibit 
volumetric growth delays concentrated in gray matter.
Unlike studies related to conditions where neurological 
ﬁ  nding associated with adults are simply extended to chil-
dren, SCD represents one of the few diseases about which we 
have more evidence in pediatric than adult populations as it 
relates to the sequelae of CVE. For example, using magnetic 
resonance imaging (MRI) with and without contrasts Wang 
et al (1998) found that infants and very young children, ages 
7 to 48 months, with no reported history of CVE neverthe-
less had evidence of silent infarctions and major cerebral 
artery stenosis at rates similar to adults.Wang et al (1998) 
also found MRI/MRA abnormalities among asymptomatic 
infants, median aged 18 months.
Several studies have (Briscoe 2001; Steen, Emudianughe 
et al 2003; Steen, Hankins et al 2003) have reported that chil-
dren with SCD experience CVE in the absence of historical 
neurological morbidity and with few, if any, visible short-term 
symptoms. Grueneich et al (2004) most recently suggested 
that radiographic imaging evidence of silent strokes may 
be associated with inconsistent and variable neurocognitive Neuropsychiatric Disease and Treatment 2007:3(6) 707
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functioning as well as possible deﬁ  cits. Several studies have 
also demonstrated that cognitive deﬁ  cits in children with SCD 
exist in the absence of relevant MRI ﬁ  ndings, and that deﬁ  cits 
are multifactoral, complex, and arise from multiple etiological 
factors (Bernaudin et al 2000; Steen, Fineberg-Buchner et al 
2005). Collectively, these studies emphasize the need for early 
detection of CVE in patients with SCD in an effort to reduce 
and prevent adult neurocognitive dysfunction.
Early detection of cerebral events and entry into rehabili-
tation services may provide children, and consequently adults 
who have SCD, with an increased likelihood of avoiding 
the cumulative effects of CVEs (Steen et al 1998). Because 
children have greater brain plasticity than their adult coun-
terparts, early rehabilitation efforts may lead to a greater 
recovery of function, compared to an adult counterpart with 
the same brain insult (Coelho-Mosch et al 2005). It is notable, 
however, that patients with SCD may manifest white matter 
hyperintensities and hypoxia that are less commonly seen 
in adult stroke victims associated with other diseases. This 
brings into question whether aggressive behavioral, psychi-
atric, and rehabilitational remediations that have historically 
worked effectively for adult victims of stroke could be used 
in pediatric and adult patients with SCD and yield similar 
positive results.
In the context of an emerging neurocognitive literature 
on adults with SCD, the current review reinforces the idea 
that early detection of pediatric asymptomatic as well as 
symptomatic lesions of the CNS associated with SCD may 
represent an important goal of medical and psychological 
advances to reduce adult neurocognitive dysfunctions in this 
chronically ill population. Results from multiple studies that 
reveal generally poorer neurocognitive and neuropsychiatric 
functioning in patients with SCD as compared to controls, 
further reinforce the parallel need for early identiﬁ  cation with 
treatment and rehabilitation of cognitive morbidities.
Increasingly, researchers and clinicians have embraced 
the notion that the absence of symptoms is not synonymous 
with absence of CVE in patients with SCD (Hogan, Kirkham 
et al 2006; Hogan, Pit-ten Cate et al 2006; Hogan, Vargha-
Khadem et al 2006). It is possible that unidentiﬁ  ed and poorly 
managed CVEs may be associated with difﬁ  cult to manage 
or even irreversible neurocognitive consequences. Given the 
importance of a healthy brain for normal childhood and adult 
development, and given that brain injury secondary to CVE 
may produce functional cognitive, social, and interpersonal 
impairments (Burlew et al 2000), it is important to screen 
for and manage neurocognitive morbidities as part of routine 
and standard of care.
This standard of care must begin with more effective 
disease management in pediatric settings (Thompson et al 
2002; Hogan, Pit-ten Cate et al 2006) to include early neu-
ropsychological testing and brain imaging. Neuroimaging in 
early childhood development may identify neuroanatomical 
substrates of CNS damage before clinical evidence is mani-
fested. Neuropsychological testing may assist in identifying 
the functional consequences of early silent and overt CVE. 
Both detection modalities assist to facilitate standards of early 
intervention and remediation of brain lesions, the reduction 
of adult cognitive and functional morbidities, and allow for 
better comparison of treatment options.
Once identiﬁ  ed via neuroimaging, young adult patients 
with SCD who have manifest CVE would likely beneﬁ  t 
from rehabilitational services commonly made available 
to much older stroke populations. Through the use of base-
line and subsequent neurocogntive assessment, patterns of 
developmental delay or impairment in SCD patients may 
ultimately inform the development of cognitive, behavioral, 
and psychosocial interventions.
Many states currently conduct brief hematological screen-
ings at birth to identify patients who have the genotype for 
SCD prior to any manifestation of symptoms. The justiﬁ  cation 
for such programs is that long-term ﬁ  nancial and healthcare 
beneﬁ  ts associated with the identiﬁ  cation, anticipation (alloca-
tion of ﬁ  nancial management and care resources), and man-
agement of SCD when conducted at birth offsets the short-term 
ﬁ  nancial cost of early detection. Similarly, the long-term and 
adult ﬁ  nancial cost of unidentiﬁ  ed juvenile SCD-associated 
CVE (lost productivity, reduced cognitive capacities, etc.) 
may exceed, exponentially, the immediate cost of an early 
assessment program. Future research that would define 
additional risk factors for pediatric CVE may yield the ability 
to image and assess, more selectively, subgroups of patients 
in their formative years, and further reduce long-term cost 
(Steen, Emudianughe et al 2003).
Schatz, White et al (2002) proposed that multifactoral 
quantitative indices of brain functioning (ie, imaging, quanti-
ﬁ  ed estimates of lesion volume, neuropsychological testing) 
may provide a better method to detect silent infarctions. 
Some patients with SCD manifest CVE asymptomatically 
or with poorly localized effects. Because there are very few 
cues signaling the need for immediate medical attention, 
the cumulative effect of “silent” events may be especially 
problematic. A single silent event may not result in signiﬁ  -
cant long-term deﬁ  cits. However, the cumulative effects of 
silent CVE on adult functioning is relatively unknown and 
worthy of study. In particular, repeated events may deplete Neuropsychiatric Disease and Treatment 2007:3(6) 708
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physiological reserves in key systems and predispose organs 
to premature failure.
Lastly, the current review reveals that, in comparison to 
earlier studies of patients with SCD, the neuropsychologi-
cal literature continues to transition from simply deﬁ  ning 
morbidity associated with stroke to currently documenting 
and studying the likely role of “silent” CVE on pediatric 
functioning and adult development (Bonner et al 1999; 
Bernaudin et al 2000; Hogan, Pit-ten Cate et al 2006; Schatz 
and McClellan 2006). It also highlights, in a longitudinal 
manner, the need for future research to explore SCD-speciﬁ  c 
factors that may impact cognitive functioning (transfusion, 
low socioeconomic status and access to preventative care, 
etc.). We must also seek to differentiate the effects of organic 
from psychosocial processes on neurocognitive functioning 
in patients with SCD.
Continued research and clinical collaboration among 
neuropsychiatrists, hematologists, pediatricians, radiologists, 
neuropsychologists, and others who provide care to patients 
with SCD may assist to more effectively identify and reduce 
the incidence of CVE and the prevalence of CVE-related 
morbidity. We must continue to re-conceptualize our clinical 
models of treatment for patients with SCD to include early 
neuropsychological, neuropsychiatric, and imaging assess-
ments as primary preventative methods.
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